News | March 10, 2009

Study Shows PAD Detection to Increase, Treatment Market to Grow

March 10, 2009 – As early detection increases for peripheral arterial disease (PAD) and more patients seek treatment, the U.S. market for peripheral vascular treatment will grow to an estimated $4.7 billion by 2015, according to iData Research, an international medical device & dental market research firm.

Currently, of the estimated 10 million people in the U.S. who suffer from lower limb Peripheral Arterial Disease (PAD), 80 percent go undiagnosed, the study revealed.

PAD is the formation of plaque in arterial blood vessels of the outer circulatory system that causes damage to the arterial wall, which in turn increases the risk of stroke. In 2008, over 4 million individuals in the U.S. had symptoms indicative of PAD, such as persistent leg cramping, numbness, fatigue and severe pain.

"Of people aged 50 to 69 with a history of smoking or diabetes, approximately 30 percent will manifest PAD," says Kamran Zamanian, Ph.D., CEO of iData Research, "This will drive sales for PAD treatment devices, particularly for devices such as stents and stent-grafts, and complementary and alternative products, like embolic protection and atherectomy devices."

In 2008, the largest segment in the U.S. market for peripheral vascular devices was for stents, which represented 28.7 percent of the overall treatment market. The stent market will grow at double digit rates through 2015, led by an increase in early diagnoses. The U.S. government and the medical community have taken an active role in improving awareness of PAD among physicians and the general population.

For more information: www.idataresearch.net

Related Content

Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion
News | Peripheral Artery Disease (PAD) | July 17, 2019
A new analysis published by The Sage Group LLC concludes that the all-cause cost of critical limb ischemia (CLI)...
Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Overlay Init